1Borhani Haghighi A, Pourmand R, Nikseresht AR. Neuro-Behcet disease. A review. Neurologist, 2005, 11 (2) : 80-89.
2Verity DH, Mart JE, Ohno S, et ai. Behcet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens,1999,54 (3):213-220.
3Avci O, Ellidokuz E, Simsek I, et al. Helicobacter pylori and Behcet's disease. Dermatology, 1999, 199 (2) : 140-143.
4Goossens PH, Verburg R J, Breedveld FC. Remission of Behcet' s syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis, 2001,60 (6) : 637.
5Hassard PV, Binder SW, Nelson V, et al. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology, 2001, 120(4) :995-999.
6Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet., 2001,358(9293) : 1644.
7Kralj D, Ceroved M, Anic B. Etiology of erythema nodosum in rheumatology outpatient clinic. Lijec Vjesn, 2011,133 ( 11 - 12 ) :370-376.
8Kisawk B, Onat AM, Pelilivan Y. Muhiclinical experiences inerythema nodosum: rheumatology clinics versus dermatology and infection disease clinics. Rheumatol Int,2013,3(2) :315-318.
9Mert A, Ozaras R, Tabak F, et al. Primary tuberculosis cases presenting with erythema nodosum. J Dermatol, 2004,31 (1) :66 -68.
10Nicol MP, Kampmann B, Lawrence P, et al. Enhanced anti- mycobacterial immunity in children with erythema nodosum and a positive tuberculin skin test. J Invest Dermatol, 2007,127 (9) : 2152-2157.
